No current committee memberships matched for this official.
Intent: To communicate Amgen's perspective on policy conditions that support innovation, investment, advanced manufacturing and high-value employment, and to contribute to transatlantic dialogue on life sciences competitiveness.
Details: Participation in a multi stakeholder life sciences roundtable on EU and Irish policy issues affecting the sector's competitiveness
Intent: To raise awareness amongst stakeholders of how Ireland can remain competitive as a destination for future global life sciences investment, by ensuring that pharmaceutical innovation is valued at all stages of the value chain, including measures to increase support for research development activities, infrastructure to support resilient manufacturing supply, and timely access to innovative medicines for Irish patients.
Details: EU and Irish life sciences policy development and competitiveness
Intent: To seek updates on Ireland’s priorities in relation to EU digital legislation during the Irish Presidency of the EU Council
Details: EU Digital Legislation
Intent: To inform the Irish government about the Section 301 investigation of the US into Germany and to discuss potential wider implications of the investigations.
Details: Bayer asked for and conducted meetings with relevant officials to discuss matters about the European pharmaceutical industry, particularly on the US 301 investigation.
Intent: Ensuring mutual understanding within the Irish European Council presidency of the implications of the USTR S301 investigation into Germany. This included a discussion on the situation regarding tariffs, as well as the idea of a pharmaceutical/life sciences taskforce to discuss matters such as this. We also wanted to understand the Irish Government's current support for such a taskforce.::As a consequence of the flow of the conversation, we also discussed the EU's Food and Feed Safety Omnibus, with the goal of briefly sharing perspectives on a Council compromise text.
Details: USTR S301 Investigation, the pharmaceutical sector trade environment and the Food and Feed Safety Omnibus
Intent: Invite non-DPOs to a CropLife Europe policy event on the proposal for the introduction of a unitary Supplementary Protection Certificate (uSPC) for Plant Protection Products (PPPs), as well as including a policy paper for background information ahead of the event.
Details: Updating of uSPC policy
Intent: That Ireland would prioritise competitiveness and innovation during its Presidency of the Council of the European Union.
Details: Encouraging Ireland to prioritise competitiveness and innovation during its Presidency of the Council of the European Union.
Intent: To raise the implications of the changes to the EU's de minimis regime on goods, in the context of cross-border trade between Ireland and the UK.
Details: Changes to the de minimis regime for low value imports.
Intent: To support policies that foster innovation, strengthen Ireland's competitiveness as a life sciences hub, and improve patient access to innovative medicines
Details: Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of the sector.
Intent: To discuss the Domestic and EU Legislative Agenda and share key priorities to enhance the competitiveness of the Irish Funds Industry
Details: Domestic & EU Legislative Agenda
